Isabel Arrillaga-Romany, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioma | 14 | 2024 | 3420 | 2.440 |
Why?
|
Brain Neoplasms | 20 | 2024 | 8986 | 1.870 |
Why?
|
Neurotoxicity Syndromes | 5 | 2023 | 299 | 1.150 |
Why?
|
Glioblastoma | 9 | 2023 | 3484 | 1.140 |
Why?
|
Histones | 7 | 2024 | 2583 | 0.910 |
Why?
|
Mutation | 13 | 2024 | 29932 | 0.720 |
Why?
|
Isocitrate Dehydrogenase | 7 | 2024 | 929 | 0.680 |
Why?
|
Imidazoles | 3 | 2024 | 1180 | 0.620 |
Why?
|
Antineoplastic Agents | 9 | 2024 | 13630 | 0.550 |
Why?
|
Angiogenesis Inhibitors | 3 | 2021 | 2049 | 0.540 |
Why?
|
Pyrimidines | 5 | 2024 | 3016 | 0.530 |
Why?
|
Critical Pathways | 1 | 2019 | 475 | 0.490 |
Why?
|
Antigens, CD19 | 1 | 2017 | 424 | 0.470 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9276 | 0.420 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2021 | 2053 | 0.370 |
Why?
|
Pyridines | 4 | 2024 | 2879 | 0.360 |
Why?
|
Receptors, Dopamine D5 | 2 | 2020 | 32 | 0.340 |
Why?
|
Brain Diseases | 1 | 2019 | 1540 | 0.340 |
Why?
|
Receptors, Dopamine D2 | 2 | 2024 | 485 | 0.330 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2017 | 2536 | 0.310 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1403 | 0.290 |
Why?
|
Central Nervous System Neoplasms | 2 | 2023 | 916 | 0.230 |
Why?
|
Oligodendroglioma | 1 | 2024 | 279 | 0.200 |
Why?
|
Neoplasms | 5 | 2022 | 22072 | 0.200 |
Why?
|
T-Lymphocytes | 3 | 2023 | 10181 | 0.200 |
Why?
|
Inositol | 1 | 2021 | 215 | 0.180 |
Why?
|
Young Adult | 9 | 2024 | 58741 | 0.180 |
Why?
|
Enzyme Inhibitors | 2 | 2023 | 3726 | 0.170 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2021 | 3765 | 0.170 |
Why?
|
Humans | 39 | 2024 | 760621 | 0.170 |
Why?
|
Tretinoin | 1 | 2022 | 519 | 0.160 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3527 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 792 | 0.160 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 642 | 0.150 |
Why?
|
Cerebellar Neoplasms | 1 | 2022 | 587 | 0.150 |
Why?
|
Medulloblastoma | 1 | 2022 | 679 | 0.140 |
Why?
|
Immunotherapy, Adoptive | 3 | 2023 | 1454 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 2 | 2024 | 5643 | 0.130 |
Why?
|
Glutarates | 1 | 2018 | 244 | 0.130 |
Why?
|
Aged | 11 | 2024 | 169152 | 0.130 |
Why?
|
Middle Aged | 15 | 2024 | 220352 | 0.130 |
Why?
|
Survival Rate | 4 | 2024 | 12808 | 0.130 |
Why?
|
Telomerase | 1 | 2021 | 746 | 0.130 |
Why?
|
Transplantation Chimera | 1 | 2017 | 595 | 0.120 |
Why?
|
Lymphoma | 1 | 2023 | 1898 | 0.120 |
Why?
|
Adult | 12 | 2024 | 219994 | 0.110 |
Why?
|
Vision Disorders | 1 | 2021 | 1084 | 0.110 |
Why?
|
Neoplasm, Residual | 1 | 2018 | 1007 | 0.110 |
Why?
|
Meningioma | 1 | 2022 | 1221 | 0.110 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3844 | 0.110 |
Why?
|
Meningeal Neoplasms | 1 | 2022 | 1249 | 0.100 |
Why?
|
Female | 16 | 2024 | 391270 | 0.100 |
Why?
|
Postoperative Care | 1 | 2018 | 1479 | 0.100 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2021 | 1067 | 0.100 |
Why?
|
Remission Induction | 1 | 2017 | 2392 | 0.100 |
Why?
|
Prognosis | 5 | 2024 | 29658 | 0.100 |
Why?
|
Disease Management | 2 | 2019 | 2514 | 0.090 |
Why?
|
Double-Blind Method | 2 | 2024 | 12427 | 0.090 |
Why?
|
Male | 16 | 2024 | 359744 | 0.090 |
Why?
|
Brain Edema | 1 | 2014 | 603 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39261 | 0.080 |
Why?
|
Brain | 4 | 2023 | 26951 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1599 | 0.080 |
Why?
|
Nervous System | 1 | 2012 | 543 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2014 | 5253 | 0.080 |
Why?
|
DNA | 1 | 2022 | 7233 | 0.080 |
Why?
|
Nervous System Diseases | 2 | 2024 | 1647 | 0.080 |
Why?
|
Image Enhancement | 1 | 2018 | 2881 | 0.070 |
Why?
|
Child | 3 | 2024 | 79806 | 0.070 |
Why?
|
Adolescent | 3 | 2024 | 87810 | 0.070 |
Why?
|
Receptors, Opioid, mu | 1 | 2008 | 166 | 0.070 |
Why?
|
Biopsy | 1 | 2019 | 6771 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2024 | 11481 | 0.070 |
Why?
|
Multiple Myeloma | 1 | 2023 | 5130 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2008 | 586 | 0.060 |
Why?
|
Hospitals | 1 | 2019 | 3928 | 0.060 |
Why?
|
Contrast Media | 1 | 2018 | 5305 | 0.060 |
Why?
|
Genomics | 1 | 2021 | 5794 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5325 | 0.060 |
Why?
|
Neuroprotective Agents | 1 | 2010 | 961 | 0.050 |
Why?
|
Benzhydryl Compounds | 1 | 2010 | 941 | 0.050 |
Why?
|
Quality of Life | 1 | 2024 | 13308 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2023 | 80372 | 0.050 |
Why?
|
Dopamine Agonists | 1 | 2024 | 352 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4775 | 0.050 |
Why?
|
Receptor, Notch1 | 1 | 2024 | 495 | 0.050 |
Why?
|
Child, Preschool | 1 | 2024 | 42063 | 0.050 |
Why?
|
Eye Pain | 1 | 2021 | 46 | 0.050 |
Why?
|
Methionine | 1 | 2022 | 569 | 0.040 |
Why?
|
Animals | 5 | 2024 | 167963 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2021 | 397 | 0.040 |
Why?
|
Cognition | 2 | 2023 | 6957 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7818 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 20509 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2022 | 8552 | 0.040 |
Why?
|
Random Allocation | 1 | 2023 | 2394 | 0.040 |
Why?
|
Emotions | 1 | 2010 | 2734 | 0.040 |
Why?
|
Cerebrospinal Fluid | 1 | 2021 | 544 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11712 | 0.040 |
Why?
|
Optic Nerve | 1 | 2021 | 567 | 0.040 |
Why?
|
Aged, 80 and over | 2 | 2019 | 58995 | 0.030 |
Why?
|
Vulnerable Populations | 1 | 2022 | 696 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 10344 | 0.030 |
Why?
|
Optic Disk | 1 | 2021 | 421 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1334 | 0.030 |
Why?
|
Astrocytes | 1 | 2024 | 1338 | 0.030 |
Why?
|
Gene Expression | 2 | 2018 | 7588 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2648 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2326 | 0.030 |
Why?
|
Eye Diseases | 1 | 2021 | 651 | 0.030 |
Why?
|
Adenine | 1 | 2021 | 975 | 0.030 |
Why?
|
Cell Lineage | 1 | 2024 | 2533 | 0.030 |
Why?
|
Brain Mapping | 1 | 2010 | 6568 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2023 | 1091 | 0.030 |
Why?
|
Disease Progression | 2 | 2022 | 13502 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2380 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2008 | 4446 | 0.030 |
Why?
|
Drug Resistance | 1 | 2018 | 1617 | 0.030 |
Why?
|
Hematologic Neoplasms | 1 | 2024 | 1895 | 0.030 |
Why?
|
Piperidines | 1 | 2021 | 1650 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2022 | 6828 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2018 | 965 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3839 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2019 | 1375 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11071 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2313 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3529 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3758 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 4 | 2021 | 36290 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4899 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1547 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2021 | 5785 | 0.020 |
Why?
|
Cohort Studies | 2 | 2024 | 41335 | 0.020 |
Why?
|
Cell Survival | 1 | 2018 | 5797 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2024 | 10446 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2019 | 2056 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2821 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 8056 | 0.020 |
Why?
|
Protein Binding | 1 | 2018 | 9335 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2299 | 0.020 |
Why?
|
Time | 1 | 2008 | 545 | 0.020 |
Why?
|
Pain | 1 | 2021 | 5066 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12965 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2021 | 14495 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15289 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2023 | 65017 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2018 | 4048 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2061 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2008 | 1900 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11152 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2010 | 2362 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4319 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2010 | 8950 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 16939 | 0.010 |
Why?
|
Oxygen | 1 | 2010 | 4193 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10827 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2010 | 7021 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 54303 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2008 | 8158 | 0.010 |
Why?
|
Mice | 1 | 2024 | 81208 | 0.010 |
Why?
|
Signal Transduction | 1 | 2018 | 23376 | 0.010 |
Why?
|
United States | 1 | 2022 | 72461 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2008 | 12766 | 0.010 |
Why?
|
Rats | 1 | 2008 | 23711 | 0.010 |
Why?
|